A Phase II study of docetaxel in patients with liver metastases from breast cancer (Q59289112)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

R E Coleman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

S P Eggleton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

S J Maling

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

D W Miles

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 May 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

541-546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383707159

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383707159

7 January 2021

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383707159

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383707159

7 January 2021

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383707159

7 January 2021

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383707159

7 January 2021

Identifiers

DOI

10.1023/A:1008383707159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10907946%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference